xianzh
wang
vincent
w
colje
jennif
maynard
antibodi
therapeut
one
fastest
grow
class
pharmaceut
annual
us
market
billion
develop
treat
varieti
diseas
includ
cancer
autoimmun
infecti
diseas
current
administ
singl
molecul
treat
singl
diseas
howev
mount
evid
cocktail
multipl
antibodi
uniqu
bind
specif
protect
mechan
may
improv
clinic
efficaci
review
progress
develop
oligoclon
combin
antibodi
treat
diseas
focus
identif
synergist
antibodi
discuss
applic
modern
antibodi
engin
technolog
produc
highli
potent
antibodi
prepar
includ
oligoclon
antibodi
cocktail
truli
recombin
polyclon
antibodi
specif
exampl
illustr
synergi
confer
multipl
antibodi
provid
diseas
caus
botulinum
toxin
cancer
immun
thrombocytopenia
bioprocess
regulatori
option
prepar
discuss
antibodi
repres
largest
fraction
biolog
market
current
billion
annual
antibodi
commerci
avail
treat
cancer
inflammatori
infecti
diseas
appeal
due
larg
part
good
safeti
profil
clear
develop
path
robust
manufactur
process
improv
cell
cultur
engin
led
yield
gl
protein
engin
allow
tailor
key
characterist
ligand
bind
affin
vivo
halflif
immunogen
nevertheless
engin
singl
antibodi
alway
result
improv
clinic
efficaci
seen
motavizumab
highli
engin
palivizumab
variant
improv
affin
respiratori
syncyti
viru
f
protein
confer
addit
clinic
benefit
contrast
therapeut
nativ
immun
respons
gener
singl
antibodi
respons
diseas
instead
complex
polyclon
respons
compris
multipl
antibodi
bind
multipl
epitop
abil
mediat
varieti
effector
function
beg
question
natur
respons
monoclon
therapi
polyclon
antiserum
first
use
immunotherapi
emil
von
behr
shibasaburo
kitasato
still
use
treat
numer
diseas
includ
caus
virus
venom
toxin
target
multipl
epitop
offer
broad
strain
protect
unlik
monotherapi
less
like
provid
select
pressur
escap
mutant
alreadi
present
popul
develop
resist
hyperimmun
immunoglobulin
previous
sensit
pathogen
knowledg
never
describ
escap
variant
individu
antibodi
readili
gener
lab
set
bloodderiv
product
intraven
immunoglobulin
ivig
limit
avail
carri
risk
bloodborn
diseas
transmiss
batchtobatch
variabl
critic
even
hightit
immunoglobulin
prepar
isol
immun
volunt
small
fraction
antibodi
bind
target
interest
fraction
exert
desir
effect
figur
result
low
specif
activ
rel
high
dose
observ
clinic
effect
recent
year
evid
accumul
support
idea
mixtur
antibodi
bind
multipl
nonoverlap
epitop
combin
benefit
engin
monoclon
antibodi
broadspectrum
activ
polyclon
therapeut
moreov
sinc
compon
antibodi
produc
individu
select
basi
affin
epitop
specif
protect
mechan
ensur
member
mixtur
contribut
overal
pharmacolog
effect
review
recent
progress
toward
develop
oligoclon
antibodi
cocktail
truli
recombin
polyclon
antibodi
therapeut
includ
manufactur
regulatori
approach
simplest
case
monoclon
antibodi
alreadi
approv
use
human
test
new
combin
approv
investig
monoclon
antibodi
tabl
instanc
disregul
epiderm
growth
factor
receptor
egfr
involv
mani
cancer
two
approv
antiegfr
monoclon
antibodi
cetuximab
panitumumab
bind
egfr
domain
iii
block
ligandreceptor
activ
downstream
signal
recent
studi
demonstr
combin
antibodi
bind
nonoverlap
epitop
effect
singl
antibodi
inhibit
tumor
growth
trigger
egfr
intern
degrad
antibodi
combin
may
also
access
novel
mechan
complementdepend
cytotox
potenti
otherwis
nonprotect
antibodi
recent
approv
biclon
combin
consist
monoclon
antibodi
trastuzumab
pertuzumab
target
differ
epitop
growth
factor
receptor
effect
reduc
progress
rate
breast
cancer
patient
shown
progress
trastuzumab
treatment
alon
remark
feat
protein
engin
singl
antibodi
bind
site
engin
bind
vegf
high
affin
k
nm
respect
enhanc
vivo
efficaci
creat
new
type
bispecif
antibodi
bind
site
bind
one
two
distinct
antigen
approach
confer
advantag
bival
bispecif
antibodi
creat
novel
antiegfr
cocktail
pedersen
et
al
systemat
test
combin
two
three
antibodi
pool
murin
antiegfr
antibodi
tumor
inhibit
activ
potent
mixtur
combin
antibodi
show
maxim
tumor
inhibit
correl
egfr
downregul
antibodi
bind
nonoverlap
epitop
egfr
domain
iii
inde
antibodi
exhibit
synergist
growth
inhibit
antibodi
test
bind
nonoverlap
epitop
suggest
may
common
strategi
spangler
et
al
examin
pairwis
combin
six
murin
antiegfr
antibodi
pair
potent
reduc
surfac
egfr
level
bind
nonoverlap
domain
iii
epitop
lead
reduc
receptor
recycl
treatment
mgkg
led
complet
tumor
regress
mice
cetuximab
alon
individu
antibodi
exhibit
partial
suppress
perform
well
preclin
studi
current
phase
ii
trial
develop
antibodi
therapeut
treat
infecti
diseas
lag
behind
cancer
singl
monoclon
antibodi
avail
palivizumab
medimmun
part
due
difficulti
associ
multipl
antigen
natur
occur
strain
variat
therapeut
may
viabl
combin
antibodi
bind
potent
neutral
epitop
trigger
appropri
effector
function
sinc
polyclon
antibodi
first
use
treat
toxinmedi
diseas
earli
effort
deconvolut
polyclon
respons
mixtur
specif
monoclon
antibodi
center
pathogen
one
studi
show
antibodi
elicit
murin
immun
bound
distinct
epitop
tetanu
toxoid
heavi
chain
human
uniqu
epitop
observ
quaternari
combin
murin
antibodi
protect
mous
model
individu
antibodi
anoth
studi
two
human
antitetanu
toxin
antibodi
provid
similar
protect
polyclon
prepar
lower
dose
mg
versu
mg
similar
studi
botulinum
toxin
bonta
show
singl
antibodi
significantli
neutral
toxin
combin
three
antibodi
bind
biotechnolog
bioprocess
engin
polyclon
antibodi
therapeut
tradit
ivig
product
contain
larg
number
antibodi
bind
varieti
antigen
fraction
bind
antigen
interest
eg
bacteri
toxin
fraction
clinic
relev
protect
antibodi
pab
eg
competit
inhibit
toxinreceptor
interact
block
toxin
endocytosi
catalysi
ivig
thu
typic
requir
larg
dose
efficaci
b
multispecif
antibodi
yield
singl
molecular
entiti
abl
bind
two
distinct
epitop
therebi
combin
eas
monoclon
antibodi
manufactur
broader
antigen
specif
nonoverlap
epitop
heavi
chain
exhibit
potenc
time
greater
human
hyperimmun
globulin
greater
singl
antibodi
analysi
detail
pharmacokinet
bonta
presenc
similar
set
antibodi
identifi
therapeut
window
passiv
immun
postintox
antibodi
thought
block
receptor
bind
toxin
intern
follow
fcdepend
hepat
clearanc
antibodytoxin
complex
engin
human
version
antibodi
develop
xoma
equimolar
mixtur
three
antibodi
potent
mous
potenc
test
equin
ivig
product
treat
one
seven
bont
serotyp
encompass
subtyp
analog
cocktail
develop
serotyp
anoth
protein
engin
feat
individu
antibodi
engin
bind
epitop
present
multipl
subtyp
even
multipl
serotyp
high
affin
specif
could
potenti
combin
creat
singl
cocktail
broader
strain
coverag
second
cocktail
develop
neutral
rabi
viru
high
titer
human
equin
polyclon
immunoglobulin
remain
standard
care
crucel
holland
bv
identifi
two
human
antibodi
immun
human
bind
nonoverlap
epitop
rabi
glycoprotein
high
affin
nm
respect
antibodi
neutral
rabi
viru
bind
conform
epitop
antigen
site
ii
bind
linear
epitop
site
residu
bind
conform
epitop
within
site
iii
monoclon
antibodi
alon
shown
neutral
street
isol
similar
rabi
ivig
howev
binari
combin
neutral
strain
least
potent
ivig
hamster
model
critic
escap
variant
mutat
epitop
neutral
vice
versa
vitro
select
variant
escap
antibodi
unsuccess
binari
cocktail
safe
human
administ
conjunct
rabi
vaccin
phase
ii
clinic
trial
recombin
polyclon
antibodi
therapeut
wang
colje
maynard
tabl
oligoclon
polyclon
antibodi
therapeut
develop
addit
antibodi
cocktail
develop
treat
infecti
diseas
although
effect
yet
demonstr
clinic
trial
tabl
merck
medarex
recent
present
promis
phase
ii
clinic
data
show
biclon
therapeut
target
c
difficil
toxin
b
abl
lower
incid
recurr
patient
administ
combin
vancomycin
metronidazol
antibodi
current
phase
iii
trial
liscense
merck
individu
monoclon
biclon
combin
crucel
pursu
biclon
cocktail
sar
coronaviru
preclin
data
also
present
demonstr
effect
biclon
hepat
c
viru
vitro
anim
model
triclon
mixtur
broadli
neutral
antihiv
antibodi
bind
fusogen
conform
epitop
within
membran
proxim
region
assess
phase
ii
trial
six
fourteen
volunt
show
partial
complet
control
viremia
binari
mixtur
antibodi
bind
nonoverlap
bind
site
glycandepend
epitop
region
viral
spike
trimer
demonstr
neutral
hiv
strain
vitro
biclon
triclon
antibodi
function
synergist
neutral
target
pathogen
target
one
epitop
yet
still
vulner
mutat
target
epitop
jim
mark
group
ucsf
observ
target
bonta
minimum
three
antibodi
requir
effect
neutral
point
mutat
epitop
shift
three
antibodi
could
caus
antibodi
cocktail
becom
ineffect
event
less
like
occur
particular
target
antigen
could
hazard
mutabl
pathogen
thu
mani
case
complex
polyclon
mixtur
may
requir
confer
adequ
protect
activ
may
relev
clinic
case
aggreg
drug
would
enabl
protect
complex
diseas
reduc
potenti
immunogen
individu
compon
rhesu
antigen
rhd
select
develop
rozrolimumpab
first
class
recombin
polyclon
therapeut
symphogen
current
plasmaderiv
polyclon
antibodi
high
titer
rhesu
antigen
rhig
antigen
standard
care
treat
immun
thrombocytopenia
itp
prevent
matern
rhdsensit
rhd
woman
carri
rhd
fetu
treat
hemolyt
diseas
newborn
itp
platelet
opson
autoantibodi
destroy
fcmediat
phagocytosi
ivig
rhig
specul
protect
itp
opson
red
blood
cell
bind
macrophag
fcgriiia
receptor
outcompet
antibodybound
platelet
notion
support
evid
red
blood
cell
clearanc
correl
antirhd
coverag
sinc
rhig
current
purifi
serum
immun
male
volunt
experi
period
suppli
shortag
recogn
singl
antigen
target
effort
develop
recombin
antibodi
therapi
analysi
rhdrespons
antibodi
repertoir
alloimmun
women
reveal
consider
conserv
includ
strong
prefer
v
h
gene
segment
among
eight
women
analyz
five
share
ident
vdj
usag
cdr
spite
appar
conserv
efficaci
monoclon
antibodi
cocktail
yet
identifi
godeau
et
al
observ
transient
respons
one
seven
patient
mgkg
dosag
dose
increas
restrict
toxic
biclon
mixtur
antibodi
bind
loop
epitop
use
isotyp
respect
show
efficaci
similar
rhig
threefold
higher
dose
care
analysi
protect
confer
combin
six
antibodi
suggest
specif
epitop
recogn
antibodi
isotyp
key
variabl
explan
rhig
monoclon
efficaci
mgkg
dose
may
antigen
natur
rhd
epitop
small
overlap
observ
mutat
thu
subtl
epitop
specif
may
requir
effici
engag
rhd
fcgriiia
simultan
differ
individu
differ
requir
provid
coverag
possibl
design
combin
individu
antirhd
antibodi
bind
observ
rhd
variant
antibodi
deriv
lymphocyt
eight
rhd
women
high
antirhd
titer
product
recent
test
phase
iii
doseescal
studi
mgkg
subject
overal
patient
show
respons
day
mgkg
dose
eight
respond
similar
respons
rate
seen
rhig
requir
approxim
fivefold
dose
increas
follow
trailblaz
path
led
sever
addit
recombin
polyclon
therapeut
develop
symphogen
perform
preclin
test
recombin
polyclon
smallpox
vaccinia
character
antibodi
repertoir
ten
immun
individu
antibodi
combin
identifi
mirror
divers
specif
human
respons
affin
rang
nm
enrich
immunoglobulin
requir
mg
protect
mice
recombin
mixtur
recogn
matur
envelop
virion
protect
mg
mixtur
recogn
envelop
virion
protect
mg
decreas
importantli
antibodi
character
beyond
abil
bind
viru
symphogen
addit
phase
trial
ongo
mixtur
six
antibodi
recogn
three
egfr
variant
egfr
tabl
excelimmun
employ
set
five
human
antibodi
recogn
aureu
includ
methicillinresist
aureu
mrsa
strain
vivo
studi
show
protect
exceed
confer
monoclon
antibodi
fulli
protect
mice
lethal
dose
bacteria
mgkg
dose
five
antibodi
one
bind
identifi
antigen
other
bind
either
cell
surfac
solubl
protein
mani
aureu
toxin
encod
phage
result
consider
divers
strain
case
acut
sepsi
present
optim
clinic
outcom
may
obtain
treatment
singl
therapeut
broad
strain
coverag
rather
first
identifi
specif
strain
treat
special
drug
final
excel
test
case
recombin
polyclon
antibodi
therapi
may
diseas
caus
bordetella
primarili
b
pertussi
bordetella
express
known
virul
factor
critic
clear
serolog
correl
protect
current
avail
acellular
vaccin
includ
one
five
antigen
known
induc
strong
humor
immun
respons
spite
broad
vaccin
coverag
diseas
persist
incid
increas
dramat
recent
year
high
infant
morbid
mortal
rate
howev
treatment
hightit
antipertussi
toxin
ivig
shown
revers
diseas
symptom
seven
day
infect
mice
phase
ii
trial
infant
shown
reduc
number
whoop
also
sever
exampl
literatur
synergist
antibodi
combin
potenc
surpass
polyclon
antisera
mice
sinc
key
antigen
wellcharacter
case
neutral
antibodi
protect
epitop
alreadi
identifi
antibodi
could
ration
combin
identifi
potent
protect
cocktail
antibodi
could
individu
engin
trait
like
correl
protect
includ
high
affin
recognit
circul
clinic
strain
character
mechan
protect
key
question
develop
recombin
cocktail
polyclon
antibodi
therapeut
antibodi
combin
minim
collect
synergist
potent
protect
yet
robust
antigen
variat
answer
may
lie
defin
antibodi
repertoir
respond
differ
epitop
present
antigen
comprehens
collect
protect
antibodi
bind
differ
epitop
select
character
engin
older
work
use
phage
librari
gener
donor
pbmc
approach
suffer
loss
nativ
lightheavi
chain
pair
heterolog
express
constraint
excit
newer
technolog
develop
isol
sequenc
variabl
region
present
antigenspecif
plasmablast
correl
serum
antibodi
observ
proteom
overal
serum
respons
recogn
singl
antigen
appear
oligoclon
discret
number
clade
result
initi
vdj
recombin
event
follow
somat
hypermut
circul
repertoir
multipl
clade
member
highest
affin
highli
mutat
persist
perhap
provid
plastic
respond
antigen
variant
antibodi
present
circul
repertoir
exhibit
affin
nm
consist
expect
base
limit
b
cell
receptor
signal
competit
limit
antigen
repertoir
encod
antibodi
high
affin
larg
antigen
complex
antigen
within
clade
increas
affin
observ
gene
progress
alter
via
somat
hypermut
analysi
plasma
cell
tetanu
toxin
immun
observ
uniqu
vh
vl
rearrang
respect
one
donor
immun
influenza
vaccin
yield
uniqu
vh
rearrang
overal
affin
rang
nm
singl
antigen
present
multipl
antigen
site
includ
neutral
nonneutr
immunodomin
weakli
immunogen
epitop
nativ
polyclon
respons
includ
antibodi
recogn
includ
decoy
epitop
highli
immunogen
domin
polyclon
respons
weakli
nonprotect
figur
instanc
rhd
appear
possess
one
major
epitop
fortuit
recogn
high
affin
germlin
antibodi
head
domain
influenza
ha
five
uniqu
site
key
advantag
recombin
polyclon
therapeut
compris
exclus
high
affin
antibodi
bind
potent
neutral
epitop
character
protect
mechan
recapitul
exceed
potenc
natur
respons
manufactur
individu
monoclon
antibodi
welldevelop
primarili
use
stabli
transfect
cho
cell
fedbatch
cultur
follow
downstream
purif
product
character
accord
standard
set
center
drug
evalu
research
cder
fda
step
typic
involv
protein
affin
size
exclus
chromatographi
follow
analys
structur
integr
sdspage
peptid
map
free
sulfhydryl
monosaccharid
oligosaccharid
analys
simpl
approach
gener
antibodi
cocktail
especi
alreadi
receiv
approv
monoclon
therapeut
process
molecul
parallel
combin
purif
point
administr
figur
may
favor
regulatori
perspect
consid
fda
combin
drug
rule
discuss
biclon
triclon
therapeut
compris
novel
antibodi
current
gener
similar
manner
master
cell
bank
prepar
antibodi
expand
express
purifi
separ
combin
defin
ratio
theoret
biand
triclon
mixtur
complic
thu
manufactur
monoclon
avoid
overhaul
establish
manufactur
platform
main
concern
undesir
interact
compon
antibodi
upon
combin
instanc
xoma
antibont
triclon
cocktail
produc
way
presenc
integr
compon
antibodi
monitor
hplc
chromatographi
hydrophob
interact
revers
phase
elisa
use
toxin
domain
specif
engin
bind
singl
antibodi
mixtur
cocktail
store
two
year
robust
lyophil
retain
fullantigenreact
five
month
howev
number
uniqu
molecul
increas
two
three
manufactur
cost
rise
precipit
sinc
molecul
sequenti
monopol
facil
requir
individu
character
moreov
batch
subject
failur
produc
multipl
small
batch
elimin
save
achiev
economi
scale
larger
recombin
protein
product
facil
figur
constrain
cost
strategi
develop
produc
recombin
polyclon
antibodi
singl
pot
sever
subsequ
enter
clinic
trial
processasproduct
strategi
bypass
manufactur
hurdl
associ
individu
antibodi
product
introduc
new
challeng
demonstr
reproduc
cell
growth
genom
stabil
constant
antibodi
ratio
integr
compon
antibodi
meru
solv
gener
oligoclon
tm
singl
stabl
cell
line
express
one
light
common
chain
three
heavi
chain
produc
biotechnolog
bioprocess
engin
consist
antibodi
mixtur
three
uniqu
bind
site
pgcellday
cell
divis
process
work
sinc
mani
case
light
chain
promiscu
form
function
bind
site
varieti
heavi
chain
case
ligandspecif
heavi
chain
select
human
fab
phage
librari
contain
singl
rearrang
light
chain
although
meru
develop
transgen
mous
singl
human
light
chain
divers
human
heavi
chain
develop
technolog
contrast
three
approach
explor
combin
stabl
cell
line
creat
polyclon
master
cell
bank
challeng
consist
growth
antibodi
product
rate
magnifi
sinc
small
rate
differ
lead
larg
differ
final
antibodi
mixtur
one
approach
sympress
reli
sitespecif
flp
recombinas
introduc
antibodi
express
cassett
singl
transcript
permiss
site
genom
favor
consist
growth
express
equal
number
uniqu
cell
line
combin
yield
work
cell
bank
result
polyclon
antibodi
mixtur
show
similar
composit
measur
ion
exchang
profil
activ
four
l
bioreactor
lot
consist
achiev
spite
differ
express
level
addit
standard
analys
use
character
monoclon
antibodi
robust
productspecif
liquid
chromatographymass
spectrometri
method
develop
unambigu
quantifi
antibodi
ratio
base
light
chain
consist
allow
symphogen
carri
clinic
trial
approv
process
singl
therapeut
entiti
second
approach
sympress
ii
randomli
integr
antibodi
gene
dhfr
cho
cell
line
gene
amplif
methotrex
select
high
express
clone
expand
combin
form
polyclon
master
cell
bank
process
evalu
two
group
six
antibodi
recogn
vaccinia
respiratori
syncyti
viru
polyclon
prepar
produc
pgcellday
stabl
antibodi
composit
assess
ion
exchang
chromatographi
cell
gener
third
approach
adenoassoci
viru
rep
protein
mediat
stabl
integr
antibodi
gene
hek
cell
earli
appear
rapid
yet
provid
control
final
antibodi
ratio
mixtur
five
line
shown
consist
express
level
stabl
antibodi
ratio
day
polyclon
immunoglobulin
therapi
safe
use
treat
human
diseas
decad
clinic
trial
ongo
new
indic
tabl
regul
cber
bloodderiv
product
extens
describ
activ
standard
establish
antigenenrich
ivig
sinc
deriv
human
volunt
equin
sourc
subject
limit
term
scalabl
suppli
shortfal
individu
antibodi
never
isol
prepar
character
bulk
activ
necessarili
includ
mani
antibodi
inert
bind
antigen
relev
diseas
figur
monoclon
antibodi
cocktail
may
address
ivig
suppli
issu
well
provid
novel
drug
diseas
neglig
risk
transmiss
diseas
given
recombin
biolog
like
fall
regul
made
cder
includ
combin
drug
rule
titl
code
feder
regul
cfr
indic
compon
assess
safeti
efficaci
individu
well
combin
thu
mixtur
two
antibodi
three
clinic
trial
may
requir
antibodi
antibodi
binari
combin
quickli
becom
costprohibit
number
antibodi
increas
unless
previous
approv
antibodi
consid
antiegfr
combin
addit
consist
product
lack
lottolot
variabl
must
ensur
antibodi
cocktail
combin
postpurif
recombin
polyclon
antibodi
therapeut
wang
colje
maynard
comparison
cost
associ
manufactur
develop
antibodi
combin
cost
fix
product
singl
monoclon
bispecif
antibodi
sinc
one
master
cell
line
manufactur
process
clinic
trial
requir
contrast
oligoclon
cocktail
manufactur
cost
increas
linearli
number
uniqu
antibodi
process
parallel
regulatori
cost
increas
exponenti
sinc
pairwis
combin
must
assess
safeti
recombin
polyclon
therapeut
initi
manufactur
regulatori
cost
high
establish
process
increas
increment
increas
molecular
complex
antibodi
mixtur
must
adher
product
qualiti
consist
requir
singl
monoclon
given
monoclon
produc
cho
cell
glycosyl
variat
microheterogen
affect
efficaci
long
vivo
halfliv
regulatori
requir
strict
instanc
hepexb
combin
two
monoclon
antibodi
hepat
b
hbv
report
posit
result
phase
iib
studi
termin
reportedli
due
oper
econom
challeng
surround
design
phase
iii
trial
rule
appli
recombin
polyclon
antibodi
produc
singl
bioreactor
depend
perspect
recombin
polyclon
mere
antibodi
cocktail
produc
singl
bioreactor
compon
would
expect
wellcharacter
contribut
efficaci
possibl
produc
compon
individu
consid
monoclon
antibodi
deriv
regul
cder
altern
recombin
polyclon
highli
potent
less
complex
variant
ivig
case
individu
antibodi
would
expect
contribut
pharmacolog
effect
long
product
efficaci
safe
reproduc
manufactur
instanc
symphogen
lead
antirhd
product
includ
uniqu
molecular
entiti
phase
ii
trial
demonstr
similar
activ
much
lower
dose
antirhesusd
ivig
key
question
antibodi
essenti
whether
three
antibodi
provid
pharmacolog
effect
relev
primarili
effect
manufactur
complex
dose
infecti
diseas
complex
polyclon
less
import
singl
antibodi
becom
smaller
chanc
point
mutat
combin
point
mutat
render
organ
complet
resist
monoclon
antibodi
establish
versatil
platform
treat
mani
diseas
singl
antibodi
bind
singl
epitop
inher
limit
even
engin
high
ligand
bind
affin
optim
pharmacokinet
effector
function
excit
new
approach
next
gener
antibodi
therapeut
mixtur
individu
antibodi
select
capit
function
synergi
inhibit
gener
escap
variant
advanc
antibodi
repertoir
character
facilit
deconvolut
polyclon
immun
respons
minim
set
antibodi
recogn
complementari
epitop
character
mechan
protect
prove
key
select
antibodi
inclus
cocktail
similarli
transform
new
technolog
emerg
term
highli
polyclon
recombin
antibodi
therapeut
led
pioneer
antirhd
product
first
truli
polyclon
recombin
antibodi
therapeut
enter
market
establish
clear
regulatori
path
valid
manufactur
process
expect
see
mani
follow
